Our approach is designed to improve testing efficiency when compared with multiple, single-biomarker tests1
The Roche Foundation Medicine platform leverages next-generation sequencing (NGS) technology to examine regions of the tumour genome that common diagnostic techniques such as PCR/IHC/FISH, and multigene hotspot NGS tests may miss.2–11 Comprehensive genomic profiling (CGP) detects the four main classes of genomic alterations–base substitutions, insertions and deletions, copy number alterations and gene rearrangements–in a comprehensive set of over 300 cancer‑relevant genes, and reports tumour mutational burden (TMB) and microsatellite instability (MSI).*2,6,7,12,13–17
How is CGP different to existing diagnostic tests?
Multigene hotspot NGS tests
Comprehensive genomic profiling